Skip to main content

Advertisement

Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease

Fig. 1

Kaplan-Meier plot of time to first event of any injury including fall. “Patients at Risk” shows the number of evaluable patients at each time point by treatment group. “Cases” shows the number of new cases of fall/injury occurring between the corresponding time point and the next time point (e.g., for 12 mg, there were 43 new cases of fall/injury between week 0 and week 13). A difference in the risk of fall/injury between verubecestat and placebo became apparent after 13 weeks and then increased over time

Back to article page